How hot is Hong Kong's biotech IPO market? Two biotechs just raised $800M total

A pair of Chinese biotechs have collectively hauled in close to $800 million upon their public debuts in Hong Kong, tucking two hefty entrants to the steady stream of HKEX IPOs. Everest Medicines raised $423 million to bankroll its pipeline of in-licensed drugs, while Genor Biopharma is pouring its $371 million proceeds into the cancer and autoimmune pipeline.

Both had closed megarounds in June just before applying for a listing, highlighting the global nature of the current biotech boom. Hillhouse played a big role in both crossover financings, as Everest reaped $310 million and Genor grabbed $160 million.

The most high-profile asset in Everest’s portfolio at the moment is Trodelvy, the crown jewel of Gilead’s $21 billion buyout of Immunomedics. The company set its eyes on the antibody-drug conjugate long before Gilead did, striking a landmark deal to in-license a therapy that had just been rejected by the FDA.

Cancer is just one of many areas Everest is building around.

With help from its deep-pocketed and well-connected founders at C-Bridge Capital, the biotech brought in top execs as well as a wide range of programs in immunology, cardio-renal and infectious diseases.

The company said the IPO cash will fund development and commercialization of its four anchor products all in pivotal trials — other planned clinical work and more BD activities. It priced at $7.10 (HK$55) per share.

For Genor, the cash infusion pushes them over the finish line with its in-house breast cancer drug coprelotamab, for which Phase III studies are complete and an NDA is planned for later this year.

“We aim to be a leading breast cancer therapies provider among domestic firms in three to five years,” CEO Guo Feng told the South China Morning Post. “We are building a sales team for multiple drug candidates in this category, and our superior manufacturing capabilities mean we can make a good profit even in a competitive market.”

After that, he has also lined up a slate of antibodies against some of the best-known targets in oncology such as PD-1 and VEGF. Then there’s a new research lab in San Francisco dedicated to generating bispecifics.

Genor priced at $3.10 (HK$24) a pop to bring in substantially more than $200 million, which it was reportedly eyeing last year before bringing in the Series B

MOCTEN

 

In January 1993, EUNET launched the first online news website, MOCTEN.com (stands for Music Opinions Culture Technology Economy News), led by Eric Bach, Teus Hagen, Peter Collinson, Julf Helsingius, Daniel Karrenberg,...  Read more

×